#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



## T COLOR DE SENSO IN RECOLOR DE LA PRIME DE LA PRIME

(43) International Publication Date 22 August 2002 (22.08.2002)

PCT

# (10) International Publication Number WO 02/064572 A1

- (51) International Patent Classification?: C07D 239/96, 401/12, 405/12, 409/12, 405/14, 409/14, 471/04, 403/12, 403/10, 410/10, 413/10, 401/06, A61K 31/5025, 31/505
- (21) International Application Number: PCT/EP02/01979
- (22) International Filing Date: 11 February 2002 (11.02.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/268,661

14 February 2001 (14.02.2001) US

- (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANDRIANJARA, Charles [FR/FR]; 3, rue Auguste Daix, F-94260 Fresnes (FR). CHANTEL-BARVIAN, Nicole [US/US]; 1225 Olivia Avenue, Ann Arbor, MI 48104 (US). GAUDILLIERE, Bernard [FR/FR]; 28, rue de Zilina, F-92000 Nanterre (FR). JACOBELLI, Henri [FR/FR]; 65, avenue du Général de Gaulle, F-91550 Paray Vieille Poste (FR). ORTWINE, Daniel, Fred [—/—]; 3594 Oak Park Drive, Saline, MI 48176 (US). PATT, William, Chester [US/US]; 160 East Summit, Chelsea, MI 48118 (US). PHAM, Ly [US/US]; 1609 Buchanana SW, Grand Rapids, MI 49507 (US). KOSTLAN, Catherine, Rose [US/US]; 9876 Moon Road, Saline, MI 48176 (US). WILSON, Michael, William [US/US]; 3520 Charter Place, Ann Arbor, MI 48105 (US).
- (74) Agents: HIRSCH, Denise et al.; Pfizer Global Research and Development, Fresnes Laboratories, 3-9, rue de la Loge, B.P. 100, F-94265 Fresnes Cedex (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,

[Continued on next page]

(54) Title: OUINAZOLINES AS MMP-13 INHIBITORS

(57) Abstract: A compound selected from those of formula (I): in which:  $R_1$  represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted, W represents oxygen, sulphur, or =N-R', in which R' is as defined in the description,  $X_1$ ,  $X_2$  and  $X_3$  represent nitrogen or -C-R<sub>6</sub> in which R<sub>6</sub> is as defined in the description, Y represents oxygen, sulphur, -NH, or -N(C<sub>1</sub>-C<sub>6</sub>)alkyl, Z represents oxygen, sulphur, -NR<sub>7</sub> in which R<sub>7</sub> is as defined in the description, and optionally carbon atom, n is an integer from 1 to 8 inclusive,  $Z_1$  represents -CR<sub>8</sub>R<sub>9</sub> wherein R<sub>8</sub> and R<sub>9</sub> are as defined in the description, A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system, m is an integer from 0 to 7 inclusive, the group(s) R<sub>2</sub> is (are) is as defined in the description, R<sub>3</sub> represents hydrogen, alkyl, alkenyl, alkynyl, or a group of formula: in which  $Z_2$ , B, R<sub>5</sub>, P and q are as defined in the description, optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.



4572

## INTERNATIONAL SEARCH REPORT

in al Application No PCT/EP 02/01979

			PCI	/EP 02/01979		
IPC 7	FICATION OF SUBJECT MATTER C07D239/96 C07D401/12 C07D40! C07D409/14 C07D471/04 C07D40: C07D413/10 C07D401/06 A61K31, o International Patent Classification (IPC) or to both national classification.	3/12 CO7D4 /5025 A61K3	03/10	CO7D405/14 CO7D401/10		
	SEARCHED	ilcation and IPC				
	ocumentation searched (classification system followed by classific	ation symbols)	·			
IPC 7	CO7D A61K					
Documenta	ilon searched other than minimum documentation to the extent tha	u such documents are	Included in	the fields searched		
	•	•				
Electronic d	lata base consulted during the international search (name of data	base and, where prad	ical, search	terms used)		
WPI Da	ta, PAJ, BEILSTEIN Data, EPO-Inter	nal, CHEM AB	S Data			
C DOCUM	ENTS CONCIDEDED TO DE DEL EUANT					
Category °	ENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the	roles ant naccenne		Relevant to claim No.		
Category	Oralion of document, with inducation, where appropriate, of the	Televalli passagas		Helevant to cidiiti 140.		
χ	LIVERTON N J ET AL: "Nonpeptide	e		17,18		
	glycoprotein IIb/IIIa inhibitors:			·		
	substituted quinazolinediones an quinazolinones as potent fibrino					
	receptor antagonists"					
	BIOORGANIC & MEDICINAL CHEMISTR					
	OXFORD, GB, vol. 8, no. 5, 3 March 1998 (199					
	pages 483-486, XP004136889 ISSN: 0960-894X					
	see compound 7 page 481		•			
X	H OGAWA ET AL: "Studies on positive			17,18		
	inotropic agents V" CHEM PHARM BULL,					
	vol. 36, no. 6, 1988, pages 2253-2258, XP001080174					
	see compound X chart I					
	·	-/				
X Furt	her documents are listed in the continuation of box C.	χ Patent far	nily member	's are listed in annex.		
Special categories of cited documents:						
*A* document defining the general state of the art which is not clied to understand the principle or theory underlying the						
"E" earlier document but published on or after the International "X" document of particular r				plar relevance; the claimed invention		
"L" docume	el or cannot be considered to when the document is taken alone					
which is cited to establish the publication date of another citation or other special reason (as specified)  'O' document referring to an oral disclosure, use, exhibition or comment referring to an oral disclosure, use, exhibition or comment is combined with one or more other such document is combined with the combined with the c						
other	means ent published prior to the international filing date but	being obvious to a person skilled				
later ti	han the priority date claimed		& document member of the same patent family			
Date of the actual completion of the international search  Date of mailing of the international search report						
4	June 2002	25/06	25/06/2002			
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized offi	Authorized officer			
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,	Scrut	Scruton-Evans, I			
	Fax: (+31-70) 340-3016	Scrut	Scruton-Evans, I			

### INTERNATIONAL SEARCH REPORT

Ini tal Application No PCT/EP 02/01979

			101/61 06	, 013, 3				
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 //(C07D471/04,239:00,221:00)								
According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS SEARCHED								
Minimum documentation searched (classification system followed by classification symbols)								
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched								
Electronic di	ata base consulted during the International search (name of data ba	se and, where practical	, search Iarms used					
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT	- <u></u>						
Category *	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.				
P,X	DATABASE CHEMCATS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS,OHIO,US; XP002201020 ORDER NO A1240/0056923 & "SCREENING COLLECTION" 28 March 2000 (2000-03-28) , ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY , 47 LENINSKY PROSPECT, MOSCOW, 117913 RUSSIA/		1					
	ner documents are listed in the continuation of box C.	X Patent family	members are listed	in annex.				
"A' docume conside "E' earlier of filing de "L' docume which i citation "O' docume other n "P' docume later th	ant defining the general state of the art which is not ered to be of particular relevance to be of particular relevance to the organization of the comment but published on or after the international ate on the property claim(s) or is clied to establish the publication date of another or other special reason (as specified) the publication or the property of the published prior to the international filling date but	or priority date and cited to understan invention  "X" document of particular cannot be conside involve an invention  "Y" document of particular cannot be conside document is comb ments, such comb in the art.  "&" document member	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the ctaimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled					
Name and m	nailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-3016  Fax: (+91-70) 340-3018	Authorized officer  Scruton	-Evans, I					